Point72 Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $67.8M | Buy |
358,634
+183,634
| +105% | +$32.1M | 0.09% | 271 |
|
|
2025
Q4 | $29.8M | Buy |
175,000
+163,145
| +1,376% | +$25M | 0.03% | 659 |
|
|
2025
Q3 | $1.56M | Buy |
+11,855
| New | +$1.42M | ﹤0.01% | 1542 |
|
|
2025
Q2 | – | Sell |
-173,870
| Closed | -$21.6M | – | 2409 |
|
|
2025
Q1 | $21.6M | Buy |
173,870
+89,719
| +107% | +$11.7M | 0.05% | 434 |
|
|
2024
Q4 | $10.4M | Sell |
84,151
-184,632
| -69% | -$21.8M | 0.02% | 688 |
|
|
2024
Q3 | $29.9M | Buy |
268,783
+86,768
| +48% | +$9.51M | 0.08% | 305 |
|
|
2024
Q2 | $19.4M | Buy |
+182,015
| New | +$20M | 0.05% | 410 |
|
|
2023
Q4 | – | Sell |
-64,624
| Closed | -$8.06M | – | 2465 |
|
|
2023
Q3 | $8.36M | Buy |
+64,624
| New | +$8.61M | 0.02% | 714 |
|
|
2023
Q2 | – | Sell |
-87,909
| Closed | -$12.9M | – | 2470 |
|
|
2023
Q1 | $12.9M | Buy |
87,909
+76,109
| +645% | +$11.3M | 0.04% | 475 |
|
|
2022
Q4 | $1.88M | Sell |
11,800
-380,100
| -97% | -$55.7M | 0.01% | 945 |
|
|
2022
Q3 | $52.2M | Buy |
391,900
+98,631
| +34% | +$15M | 0.21% | 123 |
|
|
2022
Q2 | $45.8M | Sell |
293,269
-182,905
| -38% | -$28.2M | 0.19% | 139 |
|
|
2022
Q1 | $74.1M | Sell |
476,174
-487,650
| -51% | -$70.8M | 0.29% | 78 |
|
|
2021
Q4 | $123M | Buy |
963,824
+214,524
| +29% | +$28.2M | 0.49% | 25 |
|
|
2021
Q3 | $97.6M | Buy |
+749,300
| New | +$113M | 0.43% | 39 |
|
|
2020
Q4 | – | Sell |
-326,289
| Closed | -$46.5M | – | 1021 |
|
|
2020
Q3 | $46.5M | Sell |
326,289
-19,850
| -6% | -$2.46M | 0.24% | 103 |
|
|
2020
Q2 | $38.2M | Buy |
346,139
+323,439
| +1,425% | +$35.8M | 0.25% | 105 |
|
|
2020
Q1 | $2.26M | Buy |
+22,700
| New | +$2.93M | 0.02% | 483 |
|
|
2019
Q4 | – | Sell |
-216,943
| Closed | -$27.8M | – | 1092 |
|
|
2019
Q3 | $27.8M | Buy |
+216,943
| New | +$29.1M | 0.17% | 168 |
|
|
2018
Q3 | – | Sell |
-35,000
| Closed | -$6.03M | – | 1104 |
|
|
2018
Q2 | $6.03M | Sell |
35,000
-15,000
| -30% | -$2.45M | 0.02% | 561 |
|
|
2018
Q1 | $7.55M | Buy |
+50,000
| New | +$7.33M | 0.03% | 487 |
|
|
2017
Q4 | – | Sell |
-74,700
| Closed | -$10.9M | – | 988 |
|
|
2017
Q3 | $10.9M | Buy |
74,700
+41,800
| +127% | +$6.32M | 0.05% | 381 |
|
|
2017
Q2 | $5.12M | Sell |
32,900
-344,004
| -91% | -$52.6M | 0.03% | 507 |
|
|
2017
Q1 | $54.7M | Buy |
376,904
+133,804
| +55% | +$17.4M | 0.3% | 83 |
|
|
2016
Q4 | $26.5M | Sell |
243,100
-109,100
| -31% | -$12.2M | 0.19% | 157 |
|
|
2016
Q3 | $42.8M | Buy |
352,200
+133,300
| +61% | +$18M | 0.3% | 84 |
|
|
2016
Q2 | $30.9M | Buy |
218,900
+144,400
| +194% | +$21.3M | 0.21% | 121 |
|
|
2016
Q1 | $9.73M | Buy |
+74,500
| New | +$9.27M | 0.07% | 294 |
|
|
2015
Q4 | – | Sell |
-21,915
| Closed | -$2.91M | – | 756 |
|
|
2015
Q3 | $2.91M | Buy |
+21,915
| New | +$3.77M | 0.02% | 513 |
|
Other funds holding JAZZ
VPM
VCM
EC
Point72 Asset Management's JAZZ Position: Q1 2026 in Review
Point72 Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 105% in Q1 2026, buying an estimated $32.1M and bringing the position to 358,634 shares worth $67.8M. The position accounts for 0.09% of the portfolio, ranked #271.
Point72 Asset Management first reported a position in JAZZ in Q3 2015 and has held it in 29 quarters since. The position peaked at $123M in Q4 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Point72 Asset Management held 358,634 shares of Jazz Pharmaceuticals worth $67.8M as of Q1 2026.
- Point72 Asset Management bought 183,634 Jazz Pharmaceuticals shares in Q1 2026, an estimated $32.1M.
- Jazz Pharmaceuticals made up 0.09% of Point72 Asset Management's portfolio in Q1 2026, its #271 holding.
- Point72 Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2015 and has held it in 29 quarters since.
- Point72 Asset Management's Jazz Pharmaceuticals position peaked at $123M in Q4 2021.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.